Cancer Supportive Care Drugs Market Size, Share & Trends Report

Cancer Supportive Care Drugs Market Size, Share & Trends Analysis Report By Therapeutic Class (G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs, ESAs), By Region, And Segment Forecasts, 2019 - 2026

  • Published Date: Jun, 2019
  • Base Year for Estimate: 2018
  • Report ID: GVR-2-68038-529-8
  • Format: Electronic (PDF)
  • Historical Data: 2015 - 2017
  • Number of Pages: 110

Table of Contents

Chapter 1 Methodology and Scope
                   1.1 Market Segmentation
                   1.2 Research Methodology
                   1.3 Research Scope and Assumptions
                   1.4 List to Data Sources
                   1.5 List of Abbreviations
Chapter 2 Executive Summary
                   2.1 Market Summary
Chapter 3 Market Variables, Trends & Scope
                   3.1 Market Lineage Outlook
                       3.1.1 Parent Market Outlook
                       3.1.2 Related/ Ancillary Market Outlook
                   3.2 Penetration & Growth Prospect Mapping
                   3.3 Product Pipeline Analysis, by Stage
                   3.4 Clinical Profiles of Disruptive Drugs
                   3.5 Regulatory Framework
                   3.6 Market Dynamics
                       3.6.1 Market Driver Analysis
                            3.6.1.1 Growing cancer prevalence and increase in number of people receiving chemotherapy
                            3.6.1.2 Large number of side effects associated with the cancer treatment
                            3.6.1.3 Fundamental shift from branded biologics to biosimilar domination in cancer associated treatment
                       3.6.2 Market Restraint Analysis
                            3.6.2.1 Rising popularity of targeted therapies for the treatment of cancer in developed countries
                            3.6.2.2 Unmet needs in cancer supportive care
                            3.6.2.3 Safety issues associated with supportive care agents
                   3.7 Patent Expiry Analysis
                   3.8 Cancer Supportive Care Drugs Market: Market Analysis Tools
                       3.8.1 Industry Analysis - Porter's
                       3.8.2 major deals & strategic alliances analysis
                            3.8.2.1 Joint Ventures
                            3.8.2.2 Mergers & Acquisitions
                            3.8.2.3 Licensing & Partnership
                            3.8.2.4 technology collaborations
                       3.8.3 MARKET Dynamics and Brand STRATEGIES
Chapter 4 Cancer Supportive Care Drugs Market: Segment Analysis, by Drug Class, 2015 - 2026 (USD Million)
                   4.1 Definitions & Scope
                   4.2 Drug Class Market Share Analysis, 2018 & 2026
                   4.3 Segment Dashboard
                   4.4 Market Size & Forecasts and Trend Analysis, 2015 to 2026 for the following
                       4.4.1 G-CSFs
                            4.4.1.1 G-CSFs market, 2015 - 2026 (USD Million)
                       4.4.2 Erythropoietin Stimulating Agents (ESA)
                            4.4.2.1 Erythropoietin Stimulating Agents market, 2015 - 2026 (USD Million)
                       4.4.3 Antiemetics
                            4.4.3.1 Antiemetics market, 2015 - 2026 (USD Million)
                       4.4.4 Bisphosphonates
                            4.4.4.1 Bisphosphonates market, 2015 - 2026 (USD Million)
                       4.4.5 Opioids
                            4.4.5.1 opioids market, 2015 - 2026 (USD Million)
                       4.4.6 NSAIDs and Others
                            4.4.6.1 NSAIDs and Others market, 2015 - 2026 (USD Million)
Chapter 5 Cancer Supportive Care Drugs Market: Regional Market Analysis
                   5.1 Regional Market Share Analysis, 2018 & 2026
                   5.2 Regional Market Dashboard
                   5.3 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
                       5.3.1 North america
                       5.3.2 Europe
                       5.3.3 Asia pacific
                       5.3.4 Latin America
                       5.3.5 Middle east & africa
                   5.4 Market Size & Forecasts, Estimates and Trend Analysis, 2018 to 2026
                   5.5 North America
                       5.5.1 North america cancer supportive care drugs market, 2015 - 2026 (USD Million)
                            5.5.1.1 U.S.
                            5.5.1.2 U.S. cancer supportive care drugs market, 2015 - 2026 (USD Million)
                            5.5.1.3 Canada
                            5.5.1.4 Canada cancer supportive care drugs market, 2015 - 2026 (USD Million)
                       5.5.2 Europe cancer supportive care drugs market, 2015 - 2026 (USD Million)
                            5.5.2.1 U.K.
                            5.5.2.2 U.K. cancer supportive care drugs market, 2015 - 2026 (USD Million)
                            5.5.2.3 Germany
                            5.5.2.4 Germany cancer supportive care drugs market, 2015 - 2026 (USD Million)
                            5.5.2.5 France
                            5.5.2.6 France cancer supportive care drugs market, 2015 - 2026 (USD Million)
                            5.5.2.7 Italy
                            5.5.2.8 Italy cancer supportive care drugs market, 2015 - 2026 (USD Million)
                            5.5.2.9 Spain
                            5.5.2.10 Spain cancer supportive care drugs market, 2015 - 2026 (USD Million)
                       5.5.3 Asia Pacific cancer supportive care drugs market, 2015 - 2026 (USD Million)
                            5.5.3.1 CHINA
                            5.5.3.2 China cancer supportive care drugs market, 2015 - 2026 (USD Million)
                            5.5.3.3 India
                            5.5.3.4 India cancer supportive care drugs market, 2015 - 2026 (USD Million)
                            5.5.3.5 Japan
                            5.5.3.6 Japan cancer supportive care drugs market, 2015 - 2026 (USD Million)
                            5.5.3.7 Thailand
                            5.5.3.8 Thailand cancer supportive care drugs market, 2015 - 2026 (USD Million)
                            5.5.3.9 South Korea
                            5.5.3.10 South Korea cancer supportive care drugs market, 2015 - 2026 (USD Million)
                       5.5.4 Latin America cancer supportive care drugs market, 2015 - 2026 (USD Million)
                            5.5.4.1 Brazil
                            5.5.4.2 Brazil cancer supportive care drugs market, 2015 - 2026 (USD Million)
                            5.5.4.3 Mexico
                            5.5.4.4 Mexico cancer supportive care drugs market, 2015 - 2026 (USD Million)
                            5.5.4.5 Argentina
                            5.5.4.6 Argentina cancer supportive care drugs market, 2015 - 2026 (USD Million)
                            5.5.4.7 Colombia
                            5.5.4.8 Colombia cancer supportive care drugs market, 2015 - 2026 (USD Million)
                       5.5.5 Middle east & Africa cancer supportive care drugs market, 2015 - 2026 (USD Million)
                            5.5.5.1 South Africa
                            5.5.5.2 South Africa cancer supportive care drugs market, 2015 - 2026 (USD Million)
                            5.5.5.3 Saudi Arabia
                            5.5.5.4 Saudi Arabia cancer supportive care drugs market, 2015 - 2026 (USD Million)
                            5.5.5.5 UAE
                            5.5.5.6 UAE cancer supportive care drugs market, 2015 - 2026 (USD Million)
Chapter 6 Cancer Supportive Care Drugs Market - Competitive Analysis
                   6.1 Recent Developments & Impact analysis, by key market participants
                   6.2 Company Categorization
                       6.2.1 Market Leader
                       6.2.2 Key innovators
                       6.2.3 Emerging Players
                            6.2.3.1 Pfizer (Hospira)
                            6.2.3.2 Heron Therapeutics
                            6.2.3.3 Spectrum Pharmaceuticals
                            6.2.3.4 Myelo Therapeutics
                   6.3 Vendor Landscape
                       6.3.1 Key Customers
                       6.3.2 Key Company market share analysis, 2018
                   6.4 Key Companies Profiled
                       6.4.1 Amgen Inc.
                            6.4.1.1 Company overview
                            6.4.1.2 Financial Performance
                            6.4.1.3 product benchmarking
                            6.4.1.4 recent developments
                       6.4.2 Merck & Co.
                            6.4.2.1 Company Overview
                            6.4.2.2 Financial Performance
                            6.4.2.3 Product benchmarking
                            6.4.2.4 Recent developments
                       6.4.3 Johnson & Johnson SeRvices, Inc.
                            6.4.3.1 Company Overview
                            6.4.3.2 Financial Performance
                            6.4.3.3 Product benchmarking
                            6.4.3.4 Recent developments
                       6.4.4 Heron Therapeutics, Inc.
                            6.4.4.1 Company Overview
                            6.4.4.2 Financial Performance
                            6.4.4.3 Product benchmarking
                            6.4.4.4 Recent developments
                       6.4.5 NOVARTIS AG
                            6.4.5.1 Company Overview
                            6.4.5.2 Financial Performance
                            6.4.5.3 Product benchmarking
                            6.4.5.4 Recent developments
                       6.4.6 TESARO, Inc.
                            6.4.6.1 Company Overview
                            6.4.6.2 Financial Performance
                            6.4.6.3 Product benchmarking
                            6.4.6.4 Recent developments
                       6.4.7 F. Hoffmann-La Roche AG
                            6.4.7.1 Company Overview
                            6.4.7.2 Financial Performance
                            6.4.7.3 Product benchmarking
                            6.4.7.4 Recent developments
                       6.4.8 HELSINN Healthcare SA
                            6.4.8.1 Company Overview
                            6.4.8.2 Product benchmarking
                            6.4.8.3 Recent developments


List of Tables

Table 1 List of Abbreviation
Table 2 Cancer supportive care market - Therapeutic classes
Table 3 Cancer supportive care R&D pipeline overview
Table 4 Product profile: RN624 (tanezumab)
Table 5 Product profile: Rolontis
Table 6 Product profile: NEPA IV (Fosnetupitant and palonosetron fixed combination)
Table 7 Product profile: Anamorelin
Table 8 Product profile: HTX-011
Table 9 Product profile: Myelo001
Table 10 Most prevalent cancers using chemotherapy and/or radiation therapy as a treatment
option in the U.S. (2016)
Table 11 Patent expiry analysis
Table 12 Major products- G-CSF
Table 13 Major products- Erythropoietin stimulating agents
Table 14 Major products- Antiemetics
Table 15 Major products- Bisphosphonates
Table 16 Major products- Opioids and non-opioid
Table 17 Product Portfolio: Epogen (epoetin alfa)
Table 18 Product Portfolio: Neupogen (filgrastim)
Table 19 Product Portfolio: Aranesp (darbepoetin alfa)
Table 20 Product Portfolio: Neulasta (pegfilgrastim)
Table 21 Product Portfolio: Xgeva (denosumab)
Table 22 Product Portfolio: Emend (aprepitant)
Table 23 Product Portfolio: Procrit/ Eprex (epoetin alfa)
Table 24 Product Portfolio: Sustol (granisetron)
Table 25 Product Portfolio: Cinvanti (aprepitant)
Table 26 Product Portfolio: Zometa (zolederonic acid)
Table 27 Product Portfolio: Zarxio (filgrastim biosimilar)
Table 28 Product Portfolio: Varubi (rolapitant)
Table 29 Product Portfolio: NeoRecormon (epoetin beta)
Table 30 Product Portfolio: Aloxi (palonosetron)


List of Figures

Fig. 1 Cancer supportive care drugs market segmentation
Fig. 2 Cancer supportive care market snapshot
Fig. 3 Parent market outlook
Fig. 4 Ancillary market outlook
Fig. 5 Penetration & growth prospect mapping
Fig. 6 Reimbursement of cancer medicines (2016)
Fig. 7 Cancer supportive care drugs market driver impact
Fig. 8 Cancer supportive care drugs: market restraint impact
Fig. 9 Cancer supportive care drugs: Porter’s Analysis
Fig. 10 Cancer supportive care drugs market: Drug class outlook key takeaways
Fig. 11 Drug class market share analysis (2018 & 2026)
Fig. 12 Cancer supportive care drugs market: Type movement analysis
Fig. 13 G-CSFs market, 2015 - 2026 (USD Million)
Fig. 14 ESAs market, 2015 - 2026 (USD Million)
Fig. 15 Antiemetics market, 2015 - 2026 (USD Million)
Fig. 16 Bisphosphonates market, 2015 - 2026 (USD Million)
Fig. 17 Opioids market, 2015 - 2026 (USD Million)
Fig. 18 NSAIDs and others market, 2015 - 2026 (USD Million)
Fig. 19 Regional market place, 2015 - 2026 (USD Million)
Fig. 20 Regional market share analysis (2018 & 2026)
Fig. 21 Regional market dashboard
Fig. 22 North America cancer supportive care drugs market, SWOT analysis, by Factor
Fig. 23 Europe cancer supportive care drugs market, SWOT analysis, by Factor
Fig. 24 Asia Pacific cancer supportive care drugs market, SWOT analysis, by Factor
Fig. 25 Latin America cancer supportive care drugs market, SWOT analysis, by Factor
Fig. 26 Middle East & Africa cancer supportive care drugs market, SWOT analysis, by Factor
Fig. 27 North America cancer supportive care drugs market, 2015 - 2026 (USD Million)
Fig. 28 U.S. cancer supportive care drugs market, 2015 - 2026 (USD Million)
Fig. 29 Canada cancer supportive care drugs market, 2015 - 2026 (USD Million)
Fig. 30 Europe cancer supportive care drugs market, 2015 - 2026 (USD Million)
Fig. 31 U.K. cancer supportive care drugs market, 2015 - 2026 (USD Million)
Fig. 32 Germany cancer supportive care drugs market, 2015 - 2026 (USD Million)
Fig. 33 France cancer supportive care drugs market, 2015 - 2026 (USD Million)
Fig. 34 Italy cancer supportive care drugs market, 2015 - 2026 (USD Million)
Fig. 35 Spain cancer supportive care drugs market, 2015 - 2026 (USD Million)
Fig. 36 Asia Pacific cancer supportive care drugs market, 2015 - 2026 (USD Million)
Fig. 37 China cancer supportive care drugs market, 2015 - 2026 (USD Million)
Fig. 38 India cancer supportive care drugs market, 2015 - 2026 (USD Million)
Fig. 39 Japan cancer supportive care drugs market, 2015 - 2026 (USD Million)
Fig. 40 Thailand cancer supportive care drugs market, 2015 - 2026 (USD Million)
Fig. 41 South Korea cancer supportive care drugs market, 2015 - 2026 (USD Million)
Fig. 42 Latin America cancer supportive care drugs market, 2015 - 2026 (USD Million)
Fig. 43 Brazil cancer supportive care drugs market, 2015 - 2026 (USD Million)
Fig. 44 Mexico cancer supportive care drugs market, 2015 - 2026 (USD Million)
Fig. 45 Argentina cancer supportive care drugs market, 2015 - 2026 (USD Million)
Fig. 46 Colombia cancer supportive care drugs market, 2015 - 2026 (USD Million)
Fig. 47 Middle East & Africa cancer supportive care drugs market, 2015 - 2026 (USD Million)
Fig. 48 South Africa cancer supportive care drugs market, 2015 - 2026 (USD Million)
Fig. 49 Saudi Arabia cancer supportive care drugs market, 2015 - 2026 (USD Million)
Fig. 50 UAE cancer supportive care drugs market, 2015 - 2026 (USD Million)
Fig. 51 Heat map analysis, by key market participants
Fig. 52 Key company market share analysis, 2018

What questions do you have? Get quick response from our industry experts. Request a Free Consultation
gvr icn

GET A FREE SAMPLE

gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself...

gvr icn

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

BBB icon D&B icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.